



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

642. CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Vanitha Ramakrishnan, PhD¹, Linlin Xu, PhD¹, Jason C. Paik, MD PhD¹, Carol Marimpietri, RN, MS¹, Eric Shen, BS², Xiaoxi Dong, PhD², Jessica Li, MSc¹, Andreas Agathangelidis³, Tian Tian, PhD¹, Aileen Cleary Cohen, MD PhD¹, Tadeusz Robak⁴, Constantine S. Tam, MD MBBS⁵, Paolo Ghia, MDPH⁶, Andrew Rawstron, PhD⁷, Jennifer R. Brown, MD PhD⁸

¹ BeiGene USA, Inc, San Mateo, CA

² Predicine, Inc., Hayward, CA

³ School of Biology, National and Kapodistrian University of Athens, Athens, Greece

⁴ Medical University of Lodz, Lodz, Poland

⁵ Alfred Hospital and University of Melbourne, Melbourne, Australia

⁶ Vita-Salute San Raffaele University, Milan, Italy

⁷ Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

⁸ Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Introduction

Zanu is a Bruton tyrosine kinase (BTK) inhibitor with high potency, selectivity, and efficacy and a favorable toxicity profile. In the phase 3 SEQUOIA study (NCT03336333; Tam et al. *Lancet Oncol.* 2022), zanu treatment demonstrated superior progression-free survival (PFS) in TN patients (pts) with CLL/SLL and without del(17p) (cohort 1) compared with BR treatment (hazard ratio [HR], 0.42; 95% CI, 0.28-0.63; 2-sided $P < .0001$). We evaluated PFS in both treatment arms in pt subgroups based on various biomarkers, including several known negative prognostic factors for CLL.

Methods

Details of the SEQUOIA study were described previously (Tam et al. *Lancet Oncol.* 2022). A total of 479 pts in cohort 1 were randomized to either zanu ($n=241$) or BR ($n=238$). Blood (CLL) or bone marrow (SLL) samples collected at screening were used for fluorescence in situ hybridization for chromosome abnormalities, cytogenetic analysis for complex karyotype (CK), next-generation sequencing (NGS) per the European Research Initiative on CLL (ERIC) for immunoglobulin heavy chain variable (IGHV) gene mutations and expressed clones, and ultrasensitive targeted NGS for mutation analysis of 106 genes. For NGS, all pathogenic mutations with variant allele frequency $\geq 1\%$ were analyzed. The association between biomarkers and PFS was quantified using the log-rank test and HR and summarized by the Kaplan-Meier method. Data cutoff was October 31, 2022.

Results

Overall, the CLL features analyzed were similarly distributed between both treatment arms (Table).

In pts with cytogenetic abnormalities, zanu demonstrated significantly better PFS than BR in those with del(11q) ($P < .001$), del(13q) ($P < .001$), trisomy 12 ($P < .01$), or CKT ≥ 3 ($P < .01$) (Table). Furthermore, zanu treatment conferred a similar PFS benefit to pts with the negative prognostic factor, del(11q) ($P = .05$) or intermediate prognostic factor, trisomy 12 ($P = .40$), compared to those without these abnormalities (Table). Notably, in the zanu arm, CKT ≥ 3 was not associated with worse PFS ($P = .18$; Table).

Pts with either mutated IGHV (mIGHV) or unmutated IGHV (uIGHV) in the zanu arm had significantly better PFS than pts in the BR arm (uIGHV: $P < .0001$; mIGHV: $P < .01$; Table); analysis was confirmed by an ERIC-certified provider. Furthermore, PFS was unaffected by IGHV mutational status in pts treated with zanu ($P = .12$). In pts with uIGHV, IGHV1-69 was the most prevalent expressed clone in both arms (zanu: 24.6% [31/126]; BR: 30.7% [39/127]). In the present study, pts with uIGHV harboring IGHV1-69 clones showed significantly better PFS with zanu vs BR ($P < .0001$).

Across all pts, the most frequently mutated genes were *ATM* (zanu: 11%; BR: 16%), *SF3B1* (zanu: 17%; BR: 21%), *NOTCH1* (zanu: 20%; BR: 20%), and *BRAF* (zanu: 11%; BR: 7%; Table). Pts with mutations associated with poor prognosis in CLL had significantly better PFS with zanu than with BR (eg, *ATM* [$P=.02$], *BRAF* [$P=.01$], *NOTCH1* [$P<.001$], *SF3B1* [$P<.001$]; Table). Furthermore, zanu-treated pts with or without mutations in *ATM* ($P=.58$), *NOTCH1* ($P=.38$), and *SF3B1* ($P=.39$) had similar PFS.

Conclusions

TN del(17p)-negative pts with CLL/SLL were evenly distributed between zanu and BR arms in SEQUOIA cohort 1 based on the biomarkers analyzed. PFS in zanu-treated pts was superior to that of BR-treated pts in all biomarker subgroups analyzed, including some known negative prognostic markers in CLL such as del11q, $CKT \geq 3$, and uIGHV. Importantly, within the zanu-treatment arm, pts with negative prognostic biomarkers showed comparable PFS benefit to pts without those markers. Like with other BTK inhibitors, ibrutinib and acalabrutinib, IGHV mutational status did not affect PFS outcome (Bartosz et al. *Hematology in Clinical Practice* 2022). However, contrary to what has been reported for TN or relapsed/refractory pts treated with ibrutinib-based regimens, $CKT \geq 3$ was not associated with worse PFS in zanubrutinib-treated patients (Rigolin et al. *Blood*. 2021; Thompson et al. *Cancer*. 2015). This study provides further evidence that zanu is a valuable first-line treatment option for pts with CLL/SLL.

Disclosures Ramakrishnan: *BeiGene*: Current equity holder in publicly-traded company, Ended employment in the past 24 months. **Xu:** *BeiGene USA*: Current Employment, Current equity holder in publicly-traded company, Research Funding. **Paik:** *BeiGene*: Current Employment, Current equity holder in publicly-traded company, Current holder of *stock options* in a privately-held company. **Marimpietri:** *BeiGene USA*: Current Employment, Current equity holder in publicly-traded company. **Shen:** *Predicine*: Current Employment, Current holder of *stock options* in a privately-held company. **Dong:** *Predicine Inc.:* Current Employment, Current equity holder in private company, Current holder of *stock options* in a privately-held company. **Li:** *BeiGene*: Current Employment, Current equity holder in publicly-traded company. **Tian:** *BeiGene*: Current Employment. **Cohen:** *BeiGene*: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. **Robak:** *Abbvie*: Honoraria; *Janssen*: Consultancy, Honoraria, Research Funding; *Regeneron*: Honoraria, Research Funding; *GSK*: Honoraria, Research Funding; *AstraZeneca*: Honoraria, Research Funding; *BeiGene*: Honoraria, Research Funding; *OctoPharma*: Honoraria, Research Funding. **Tam:** *AbbVie*: Honoraria, Research Funding; *Janssen*: Honoraria, Research Funding; *BeiGene*: Honoraria, Research Funding; *LOXO*: Honoraria; *Novartis*: Honoraria; *Roche*: Honoraria. **Ghia:** *BeiGene*: Consultancy, Honoraria, Research Funding; *AstraZeneca*: Consultancy, Honoraria, Research Funding; *Lilly/Loxo Oncology*: Consultancy, Honoraria, Research Funding; *BMS*: Consultancy, Honoraria, Research Funding; *AbbVie*: Consultancy, Honoraria, Research Funding; *Janssen*: Consultancy, Honoraria, Research Funding; *MSD*: Consultancy, Honoraria, Research Funding; *Roche*: Consultancy, Honoraria, Research Funding. **Rawstron:** *BD Biosciences*: Patents & Royalties; *Abbvie*, *Beigene*, *Innocare*, *Janssen*, *Medicxi*, *Thermo Fisher*: Honoraria; *Abbvie*, *BD Biosciences*, *Beckman Coulter*, *Beigene*, *Celgene*, *Gilead*, *Janssen*, *Pharmacyclics*, *Roche*: Research Funding; *Beigene*, *Pharmacyclics*: Consultancy. **Brown:** *Acerta/AstraZeneca*: Consultancy; *Numab Therapeutics*: Consultancy; *MEI Pharma*: Research Funding; *Merck*: Consultancy; *Alloplex Biotherapeutics*: Consultancy; *Hutchmed*: Consultancy; *BeiGene*: Consultancy, Research Funding; *Gilead*: Research Funding; *Grifols Worldwide Operations*: Consultancy; *Genentech/Roche*: Consultancy; *Abbvie*: Consultancy; *iOnc-tura*: Consultancy, Research Funding; *Pfizer*: Consultancy; *Pharmacyclics*: Consultancy; *SecuraBio*: Research Funding; *TG Therapeutics*: Research Funding; *Kite*: Consultancy; *Loxo/Lilly*: Consultancy, Research Funding.

Table. Summary of biomarker prevalence and associated PFS

Biomarkers	zanu n/N (%)	BR n/N (%)	PFS (zanu vs BR)	PFS in zanu arm (mutated vs unmutated)
del(11q)	41/239 (17)	46/238 (19)	HR, 0.26 (95% CI, 0.13-0.51) <i>P</i> <.001	HR, 1.96 (95% CI, 1.00-3.85) <i>P</i> =.05
del(13q)	149/239 (62)	142/238 (60)	HR, 0.29 (95% CI, 0.18-0.46) <i>P</i> <.001	HR, 0.91 (95% CI, 0.49-1.69) <i>P</i> =.77
trisomy 12	45/239 (19)	49/238 (21)	HR, 0.36 (95% CI, 0.17-0.76) <i>P</i> <.01	HR, 1.35 (95% CI, 0.66-2.78) <i>P</i> =.40
CKT ≥3	23/164 (14)	22/161 (14)	HR, 0.26 (95% CI, 0.10-0.67) <i>P</i> <.01	HR, 1.85 (95% CI, 0.75-4.55) <i>P</i> =.18
mIGHV	107/233 (46)	103/230 (45)	HR, 0.37 (95% CI, 0.20-0.70) <i>P</i> <.01	HR, 1.67 (95% CI, 0.87-3.23) <i>P</i> =.12
uIGHV	126/233 (54)	127/230 (55)	HR, 0.25 (95% CI, 0.16-0.39) <i>P</i> <.0001	
mTP53	15/223 (7)	13/215 (6)	HR, 0.55 (95% CI, 0.17-1.79) <i>P</i> =.31	HR, 2.86 (95% CI, 1.11-7.14) <i>P</i> =.02
mATM SNV	24/223 (11)	35/215 (16)	HR, 0.31 (95% CI, 0.11-0.85) <i>P</i> =.02	HR, 1.30 (95% CI, 0.51-3.33) <i>P</i> =.58
mBRAF SNV	24/223 (11)	14/215 (7)	HR, 0.27 (95% CI, 0.10-0.72) <i>P</i> =.01	HR, 2.44 (95% CI, 1.10-5.26) <i>P</i> =.02
mNOTCH1 SNV	45/223 (20)	43/215 (20)	HR, 0.26 (95% CI, 0.12-0.56) <i>P</i> <.001	HR, 1.39 (95% CI, 0.66-2.94) <i>P</i> =.38
mSF3B1 SNV	39/223 (17)	46/215 (21)	HR, 0.17 (95% CI, 0.06-0.44) <i>P</i> <.001	HR, 0.66 (95% CI, 0.26-1.69) <i>P</i> =.39

m, mutated; SNV, single-nucleotide variant; u, unmutated

Figure 1

<https://doi.org/10.1182/blood-2023-174543>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/1902/193641/blood-8505-main.pdf by guest on 20 May 2024